ArticleBone marrow transplantation2009
Clinical-scale generation of human anti-Aspergillus T cells for adoptive immunotherapy.
Article in Bone marrow transplantation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 64 citations in OpenAlex.
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- A novel lentiviral vector-based approach to generate chimeric antigen receptor T cells targetingmBio · 2024Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- Rapid and sustained T cell-based immunotherapy against invasive fungal disease via a combined two step procedure.Frontiers in immunology · 2023Article
- Pathogen-specific T Cells: Targeting Old Enemies and New Invaders in Transplantation and Beyond.HemaSphere · 2023Review
- Reinforcing the Immunocompromised Host Defense against Fungi: Progress beyond the Current State of the Art.Journal of fungi (Basel, Switzerland) · 2021Review
- Prophylactic antigen-specific T-cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant.Clinical & translational immunology · 2021Article
- Clinical-scale production of Aspergillus-specific T cells for the treatment of invasive aspergillosis in the immunocompromised host.Bone marrow transplantation · 2019Article
- Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus.Current hematologic malignancy reports · 2019Review
- Immunomodulation as a Therapy forJournal of fungi (Basel, Switzerland) · 2018Review
- Immunomodulation as Therapy for Fungal Infection: Are We Closer?Frontiers in microbiology · 2018Review
- The Multifaceted Role of T-Helper Responses in Host Defense against Aspergillus fumigatus.Journal of fungi (Basel, Switzerland) · 2017Review
- Review
- Adoptive T-cell therapy for fungal infections in haematology patients.Clinical & translational immunology · 2015Review
- Rapid generation of clinical-grade antiviral T cells: selection of suitable T-cell donors and GMP-compliant manufacturing of antiviral T cells.Journal of translational medicine · 2014Article
- Immunosuppressive compounds exhibit particular effects on functional properties of human anti-Aspergillus Th1 cells.Infection and immunity · 2014Article
- Robust T cell responses to aspergillosis in chronic granulomatous disease: implications for immunotherapy.Clinical and experimental immunology · 2013Article
- Monitoring of pathogen-specific T-cell immune reconstitution after allogeneic hematopoietic stem cell transplantation.Frontiers in immunology · 2013Review
- Immunotherapy of invasive fungal infection in hematopoietic stem cell transplant recipients.Frontiers in oncology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis is a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic SCT. There is a growing body of evidence that T cells are important in the host defense against Aspergillus, and adoptively transferred anti-Aspergillus T-helper 1 (T(H)) 1 cells might reduce infectious mortality in hematopoietic transplant recipients. Here we present for the first time a simple and rapid method for the clinical-scale generation of functionally active anti-Aspergillus T cells according to good manufacturing practice conditions. A total of 1.1 x 10(9) WBCs derived from a leukapheresis product were incubated with Aspergillus antigens. Stimulated cells were selected by means of the IFN-gamma secretion assay and expanded. In three independent experiments, a median number of 2 x 10(7) CD3+CD4+cells (range, 0.9-3.2 x 10(7)) were obtained within 13 days. The cultured CD3+CD4+ cells exhibited almost exclusively a memory activated T-helper cell phenotype. Upon restimulation, the generated T cells produced IFN-gamma, but no IL-4 or IL-10, indicating a T(H)1-cell population. Additionally, the cells proliferated upon restimulation and showed reduced alloreactivity compared to unselected CD4+ cells. This method of generating is suitable for future prospective trials designed to evaluate the effect of adoptive immunotherapy in hematopoietic transplant recipients with invasive aspergillosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.